NCT03000686View on ClinicalTrials.gov

Study of GSK2586881 on Acute Hypoxia and Exercise

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

January 4, 2019

Study Completion Date

January 4, 2019

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

GSK2586881

GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.

OTHER

Placebo

Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.

Trial Locations (1)

30625

GSK Investigational Site, Hanover

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03000686 - Study of GSK2586881 on Acute Hypoxia and Exercise | Biotech Hunter | Biotech Hunter